Gain in mTOR and PI3K activity, gain-of-function of AKT, and decreased or lost function of PTEN are common promoters of treatment resistance and disease progression in neoplasia (Glaviano et al., 2023; Harrer et al., 2023b). This evidence concerns the gene AKT1 and neoplasm.